(Total Views: 102)
Posted On: 09/08/2022 11:35:49 AM
Post# of 36311

$REGN News Article - Dupixent (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis https://marketwirenews.com/news-releases/dupi...21987.html


My Twitter: WhyteStocks